Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

Three Vanderbilt-Ingram Cancer Center physicians were recently named fellows of the American Society of Clinical Oncology.

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.

Members of Vanderbilt University Medical Center’s Canby Robinson Society recently joined CEO and President Jeff Balser, MD, PhD, and his wife, Melinda, at Cheekwood Botanic Hall for the Spring Donor Celebration, an annual event honoring donors for their loyal support.